|
Biogen’s Hemophilia A Candidate Clears Late-Stage Trial, Analysts Question Dosing Advantage
Biogen Idec’s positive Phase III results for its hemophilia A clotting factor candidate are pushing the company toward a U.S. filing in the first half of 2013.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives